Imidazopyrazinones (IPYs): Non-Quinolone Bacterial Topoisomerase Inhibitors Showing Partial Cross-Resistance with Quinolones
作者:Frédéric Jeannot、Thomas Taillier、Pierre Despeyroux、Stéphane Renard、Astrid Rey、Michaël Mourez、Christoph Poeverlein、Imène Khichane、Marc-Antoine Perrin、Stéphanie Versluys、Robert A. Stavenger、Jianzhong Huang、Thomas Germe、Anthony Maxwell、Sha Cao、Douglas L. Huseby、Diarmaid Hughes、Eric Bacqué
DOI:10.1021/acs.jmedchem.7b01892
日期:2018.4.26
unprecedented series of non-quinolone bacterial topoisomerase inhibitors from the Sanofi patrimony, named IPYs for imidazopyrazinones, as part of the Innovative Medicines Initiative (IMI) European Gram Negative Antibacterial Engine (ENABLE) organization. Hybridization of these historical compounds with the quinazolinediones, a known series of topoisomerase inhibitors, led us to a novel series of tricyclic
在我们寻求能够解决由革兰氏阴性菌引起的多重耐药性感染日益严重威胁的新抗生素的过程中,我们研究了赛诺菲(Sanofi)遗产中前所未有的一系列非喹诺酮类细菌拓扑异构酶抑制剂,命名为咪唑吡嗪酮类的 IPY,作为创新药物倡议 (IMI) 欧洲革兰氏阴性抗菌引擎 (ENABLE) 组织。这些历史化合物与喹唑啉二酮(一系列已知的拓扑异构酶抑制剂)的杂交使我们获得了一系列新的三环 IPY,这些 IPY 具有广谱活性、体内功效和良好的可开发性,尽管后来的分析显示存在遗传毒性风险.